T. Sourdille

发表

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk

Jennifer G. Robinson, G. De Backer, C. Shear, 2018, European heart journal. Cardiovascular pharmacotherapy.

P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)

T. Tvedt, B. Jilma, S. Berentsen, 2022, HemaSphere.

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol

Deepak L. Bhatt, R. Diaz, H. White, 2021, Circulation.

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Deepak L. Bhatt, D. Xavier, R. Diaz, 2019, Circulation. Cardiovascular quality and outcomes.